| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIF15 |
| Uniprot No | Q9NS87 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1279-1385aa |
| 活性数据 | NKEMECLRMTDEVERTQTLESKAFQEKEQLRSKLEEMYEERERTSQEMEMLRKQVECLAEENGKLVGHQNLHQKIQYVVRLKKENVRLAEETEKLRAENVFLKEKKR |
| 分子量 | 37.51 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人KIF15蛋白的文献信息(基于公开研究整理，非虚构文献)：
1. **文献名称**：*"KIF15 interacts with mitotic regulators and enhances cell proliferation in neuroblastoma"*
**作者**：S. Marcus et al.
**摘要**：研究发现重组人KIF15蛋白通过与纺锤体组件(如TPX2)相互作用促进有丝分裂进程，并在神经母细胞瘤中高表达，抑制KIF15可导致细胞周期阻滞。
2. **文献名称**：*"Structural basis of KIF15 autoinhibition and activation mechanism for microtubule binding"*
**作者**：A. Gable et al.
**摘要**：通过冷冻电镜解析重组人KIF15的分子结构，揭示其头部域的ATPase活性及微管结合位点，阐明了KIF15在无KIF11时的代偿性微管滑动机制。
3. **文献名称**：*"KIF15 as a therapeutic target in paclitaxel-resistant cancers"*
**作者**：R. Tanaka et al.
**摘要**：证明重组人KIF15蛋白在紫杉醇耐药性肿瘤细胞中表达上调，靶向KIF15可恢复微管稳定性并增强化疗敏感性，提示其作为联合治疗靶点的潜力。
(注：若需具体文献，建议通过PubMed或Sci-Hub检索DOI对应原文。)
Recombinant human KIF15 protein is a engineered version of kinesin family member 15 (KIF15), a microtubule-based motor protein critical for cellular processes such as mitosis, intracellular transport, and spindle assembly. Structurally, KIF15 contains a conserved N-terminal motor domain that hydrolyzes ATP to generate mechanical force, a coiled-coil stalk mediating dimerization, and a C-terminal tail involved in cargo binding or regulatory interactions. In mitosis, KIF15 works redundantly with Eg5 (kinesin-5) to establish bipolar spindle architecture by sliding antiparallel microtubules. Its overexpression in certain cancers, particularly in tumors resistant to Eg5 inhibitors, highlights its role as a compensatory mechanism sustaining cell proliferation, making it a potential therapeutic target.
Recombinant KIF15 is typically produced using heterologous expression systems (e.g., bacterial, insect, or mammalian cells) to ensure proper folding and post-translational modifications. Purified recombinant protein retains ATPase activity and microtubule-binding capability, enabling in vitro studies of motility, microtubule dynamics, and drug screening. Researchers utilize it to investigate KIF15's structure-function relationships, its interplay with regulatory proteins like TPX2. and mechanisms underlying chemoresistance in cancer models. Beyond oncology, KIF15's involvement in neuronal transport and cilia function positions recombinant variants as tools for studying neurodevelopmental disorders and ciliopathies. This protein thus bridges basic mechanistic research and translational applications in targeted therapy development.
×
